SCHEMBL316645

SCHEMBL316645

Oc1cnccc1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29947377 1.00
Ammonia Solution, Strong SCHEMBL28048774 0.97
SCHEMBL30001725 0.79
SCHEMBL627795 0.79
SCHEMBL8375145 0.77 LMNA (0.44)
SCHEMBL1203743 0.75
SCHEMBL2283975 0.75
SCHEMBL7670567 0.74
SCHEMBL31064872 0.72 AXL (0.41)
SCHEMBL22236422 0.72 RPS6KA3 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570631-B2 Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk BIOGEN MA INC. (US) 2026-03-10 US disclosed
EP-4688750-A1 SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF AS AMPK ACTIVATORS Pfizer Inc. (US) 2026-02-11 EP disclosed
US-20260035365-A1 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER BAYER AKTIENGESELLSCHAFT (DE) 2026-02-05 US disclosed
US-20260001898-A1 Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof ACCRO BIOSCIENCE HK LTD (HK) 2026-01-01 US disclosed
EP-4337648-B1 SUBSTITUTED HETEROCYCLIC COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2025-12-24 EP disclosed
EP-4628167-A2 SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT Alkermes, Inc. (US) 2025-10-08 EP disclosed
EP-4065585-B1 SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT ALKERMES INC (US) 2025-08-20 EP disclosed
US-20250236621-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2025-07-24 US disclosed
WO-2025137541-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2025-06-26 WO disclosed
EP-4565584-A1 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER Bayer Aktiengesellschaft (DE) 2025-06-11 EP disclosed
WO-2006100413-A2 NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF LABORATOIRES FOURNIER S.A. (FR) 2006-09-28 WO disclosed
WO-2006092731-A1 1, 2, 4-TRIAZOLE DERIVATIVES AND THEIR USE AS OXYTOCIN ANTAGONISTS PFIZER LIMTED (GB) 2006-09-08 WO disclosed
EP-0663912-B1 HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION ABBOTT LAB (US) 2001-12-12 EP disclosed
EP-1047690-A1 HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION Abbott Laboratories (US) 2000-11-02 EP disclosed
US-5948793-A 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release ABBOTT LABORATORIES (US) 1999-09-07 US disclosed
WO-1999032480-A1 HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION ABBOTT LABORATORIES (US) 1999-07-01 WO disclosed
US-5914328-A CONTROL DOPAMINE RELEASE, ACTIVATE CHOLINERGIC CHANNELS ABBOTT LABORATORIES (US) 1999-06-22 US disclosed
EP-0663912-A1 HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION ABBOTT LABORATORIES (US) 1995-07-26 EP disclosed
EP-0663912-A4 HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION. ABBOTT LAB (US) 1995-02-17 EP disclosed
WO-1994008992-A1 HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION ABBOTT LABORATORIES (US) 1994-04-28 WO disclosed